{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"Research Square"}],"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T19:26:30Z","timestamp":1787772390382,"version":"build-2784847793"},"posted":{"date-parts":[[2026,8,26]]},"group-title":"In Review","reference-count":38,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T00:00:00Z","timestamp":1787702400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2026,8,21]]},"abstract":"<title>Abstract<\/title>\n                <p>\n                  <bold>Background<\/bold>\n                  State-regulated psilocybin services have expanded access outside research settings. Patients seeking these services may have medical and psychiatric complexity not represented in clinical trials, while guidance for clinicians advising them remains limited. We introduce the Psilocybin Education and Assessment Collaborative for Excellence (PEACE), a consultation model within a traditional healthcare system developed to support patients considering Oregon Psilocybin Services (OPS).\n                  <bold>Methods<\/bold>\n                  We describe the PEACE model\u2019s structure and clinical approach, including individualized assessment, evidence appraisal, education, risk-reduction planning, and care coordination. We present two longitudinal cases illustrating clinical complexity and outcomes after accessing OPS.\n                  <bold>Results<\/bold>\n                  The first case involves a middle-aged man with alcohol use disorder who experienced early improvement after two OPS sessions and ultimately achieved abstinence through a nonlinear recovery process. During abstinence, he underwent a distressing high-dose unsupervised psilocybin experience, after which he received PEACE-supported integration care. The second case involves an older woman with major depressive disorder who completed supervised antidepressant tapers and underwent two supervised psilocybin experiences. Her depression worsened three months after the second experience, and she returned to PEACE for medication and integration support.\n                  <bold>Conclusion<\/bold>\n                  These cases illustrate the challenges of extrapolating psychedelic clinical trial findings to real-world settings and the importance of longitudinal follow-up, as early improvement may not reflect longer-term, nonlinear recovery trajectories. Consultation models such as PEACE may support informed decision-making, risk reduction, continuity of care, and integration of psilocybin-related care into existing healthcare systems.\n                <\/p>","DOI":"10.21203\/rs.3.rs-10779254\/v2","type":"posted-content","created":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T18:42:29Z","timestamp":1787769749000},"source":"Crossref","is-referenced-by-count":0,"title":["Medical and Psychiatric Consultation for Patients Considering State-Regulated Psilocybin Services: A Risk-Reduction Model and Two Illustrative Cases"],"prefix":"10.21203","author":[{"given":"Michael","family":"Sarvi","sequence":"first","affiliation":[{"name":"Oregon Health & Science University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Will","family":"Lucas","sequence":"additional","affiliation":[{"name":"University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ximena","family":"Levander","sequence":"additional","affiliation":[{"name":"Oregon Health & Science University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aryan","family":"Sarparast","sequence":"additional","affiliation":[{"name":"Oregon Health & Science University"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","unstructured":"Oregon Legislative Assembly Chapter 475A \u2014 Psilocybin Regulation. Salem, OR: Oregon Legislative Assembly. https:\/\/www.oregonlegislature.gov\/bills_laws\/ors\/ors475a.html (accessed 17 April 2026)"},{"key":"ref2","author":"Occupations","unstructured":"Colorado Natural Medicine Laws | Divisions of Professions and, Occupations https:\/\/dpo.colorado.gov\/NaturalMedicine\/Laws (accessed 17 August 2026)."},{"key":"ref3","volume-title":"Senate Bill 219: Medical Psilocybin Act","author":"New Mexico Legislature","year":"2025","unstructured":"New Mexico Legislature (2025) Senate Bill 219: Medical Psilocybin Act. New Mexico Legislature, Santa Fe, NM"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2026.1777387","article-title":"Inaugural year of regulated psilocybin services in Oregon: safety, motivations, and utilization","volume":"17","author":"Yu F","unstructured":"Yu F, Tafur J, Moreno F et al Inaugural year of regulated psilocybin services in Oregon: safety, motivations, and utilization. Front Psychiatry ; 17. Epub ahead of print 13 May 2026. 10.3389\/fpsyt.2026.1777387","journal-title":"Front Psychiatry"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.2147\/DDDT.S443177","article-title":"The Promise of Therapeutic Psilocybin: An Evaluation of the 134 Clinical Trials, 54 Potential Indications, and 0 Marketing Approvals on ClinicalTrials.gov","volume":"18","author":"Norring SA","year":"2024","unstructured":"Norring SA, Spigarelli MG (2024) The Promise of Therapeutic Psilocybin: An Evaluation of the 134 Clinical Trials, 54 Potential Indications, and 0 Marketing Approvals on ClinicalTrials.gov. Drug Des Devel Ther 18:1143\u20131151","journal-title":"Drug Des Devel Ther"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1177\/02698811241269751","article-title":"Psilocybin for Clinical Indications: A Scoping Review","volume":"38","author":"Madden K","year":"2024","unstructured":"Madden K, Flood B, Shing DY et al (2024) Psilocybin for Clinical Indications: A Scoping Review. J Psychopharmacol (Oxf) 38:1027\u20131043","journal-title":"J Psychopharmacol (Oxf)"},{"key":"ref7","first-page":"14","article-title":"Psychedelics in PERIL: The Commercial Determinants of Psychedelic Research and Practice","volume":"19","author":"Buchman DZ","year":"2024","unstructured":"Buchman DZ, Earp BD, Johnson MW et al (2024) Psychedelics in PERIL: The Commercial Determinants of Psychedelic Research and Practice. Philos Ethics Humanit Med 19:14","journal-title":"Philos Ethics Humanit Med"},{"key":"ref8","unstructured":"Compass Pathways Announces Six-Month Data from Second Phase 3 Trial Confirming Rapid and Durable Profile, https:\/\/ir.compasspathways.com\/News--Events-\/news\/news-details\/2026\/Compass-Pathways-Announces-Six-Month-Data-from-Second-Phase-3-Trial-Confirming-Rapid-and-Durable-Profile\/default.aspx (accessed 17 August 2026)."},{"key":"ref9","author":"Food US","unstructured":"Food US, Administration D Psychedelic Drugs: Considerations for Clinical Investigations, https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/psychedelic-drugs-considerations-clinical-investigations (26 June 2023)"},{"key":"ref10","unstructured":"Drug Enforcement Administration (2020) Drug Fact Sheet: Psilocybin, https:\/\/www.dea.gov\/sites\/default\/files\/2020-06\/Psilocybin-2020.pdf (June"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"1040217","DOI":"10.3389\/fpsyt.2022.1040217","article-title":"Therapeutic use of psilocybin: Practical considerations for dosing and administration","volume":"13","author":"MacCallum CA","year":"2022","unstructured":"MacCallum CA, Lo LA, Pistawka CA et al (2022) Therapeutic use of psilocybin: Practical considerations for dosing and administration. Front Psychiatry 13:1040217","journal-title":"Front Psychiatry"},{"key":"ref12","author":"Hosein MM","year":"2025","unstructured":"Hosein MM, Reid MJ, Walser S et al (2025) Considerations and Cautions for the Integration of Psilocybin into Routine Clinical Care: A Consensus Statement from the US National Network of Depression Centers\u2019 Task Group on Psychedelics and Related Compounds. eClinicalMedicine ; 89: 103517"},{"key":"ref13","unstructured":"Oregon Health Authority What Are Psilocybin Services? Oregon Psilocybin Services, https:\/\/www.oregon.gov\/oha\/ph\/preventionwellness\/pages\/psilocybin-what-are-psilocybin-services.aspx (accessed 18 April 2026)"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.64898\/2026.08.17.26360633","article-title":"Level of Preparedness to Use Psilocybin Among Individuals Seeking Psychedelic Risk Reduction: A Retrospective Study of a Pilot Psychiatric Consultation Service. Epub ahead of print 19 August 2026","author":"Harrison HV","unstructured":"Harrison HV, Gaillard M, Cook RR et al Level of Preparedness to Use Psilocybin Among Individuals Seeking Psychedelic Risk Reduction: A Retrospective Study of a Pilot Psychiatric Consultation Service. Epub ahead of print 19 August 2026. 10.64898\/2026.08.17.26360633"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"3280","DOI":"10.1038\/s41598-024-53829-z","article-title":"Development and psychometric validation of a novel scale for measuring \u2018psychedelic preparedness\u2019","volume":"14","author":"McAlpine RG","year":"2024","unstructured":"McAlpine RG, Blackburne G, Kamboj SK (2024) Development and psychometric validation of a novel scale for measuring \u2018psychedelic preparedness\u2019. Sci Rep 14:3280","journal-title":"Sci Rep"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1089\/psymed.2023.0051","article-title":"A Plea for Nuance: Should People With a Family History of Bipolar Disorder Be Excluded From Clinical Trials of Psilocybin Therapy?","volume":"2","author":"Downey AE","year":"2024","unstructured":"Downey AE, Bradley ER, Lerche AS et al (2024) A Plea for Nuance: Should People With a Family History of Bipolar Disorder Be Excluded From Clinical Trials of Psilocybin Therapy? Psychedelic Med 2:61\u201373","journal-title":"Psychedelic Med"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1055\/a-1524-2794","article-title":"Classic Psychedelic Coadministration with Lithium, but Not Lamotrigine, is Associated with Seizures: An Analysis of Online Psychedelic Experience Reports","volume":"54","author":"Nayak SM","year":"2021","unstructured":"Nayak SM, Gukasyan N, Barrett FS et al (2021) Classic Psychedelic Coadministration with Lithium, but Not Lamotrigine, is Associated with Seizures: An Analysis of Online Psychedelic Experience Reports. Pharmacopsychiatry 54:240\u2013245","journal-title":"Pharmacopsychiatry"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1002\/cncr.35010","article-title":"Psilocybin-assisted group therapy in patients with cancer diagnosed with a major depressive disorder","volume":"130","author":"Agrawal M","year":"2024","unstructured":"Agrawal M, Richards W, Beaussant Y et al (2024) Psilocybin-assisted group therapy in patients with cancer diagnosed with a major depressive disorder. Cancer 130:1137\u20131146","journal-title":"Cancer"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1001\/jamapsychiatry.2022.2096","article-title":"Percentage of Heavy Drinking Days Following Psilocybin-Assisted Psychotherapy vs Placebo in the Treatment of Adult Patients With Alcohol Use Disorder: A Randomized Clinical Trial","volume":"79","author":"Bogenschutz MP","year":"2022","unstructured":"Bogenschutz MP, Ross S, Bhatt S et al (2022) Percentage of Heavy Drinking Days Following Psilocybin-Assisted Psychotherapy vs Placebo in the Treatment of Adult Patients With Alcohol Use Disorder: A Randomized Clinical Trial. JAMA Psychiatry 79:953\u2013962","journal-title":"JAMA Psychiatry"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1001\/jamapsychiatry.2020.3285","article-title":"Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial","volume":"78","author":"Davis AK","year":"2021","unstructured":"Davis AK, Barrett FS, May DG et al (2021) Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial. JAMA Psychiatry 78:481\u2013489","journal-title":"JAMA Psychiatry"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1056\/NEJMoa2206443","article-title":"Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression","volume":"387","author":"Goodwin GM","year":"2022","unstructured":"Goodwin GM, Aaronson ST, Alvarez O (2022) Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. N Engl J Med 387:1637\u20131648","journal-title":"N Engl J Med"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1177\/0269881116675513","article-title":"Psilocybin Produces Substantial and Sustained Decreases in Depression and Anxiety in Patients With Life-Threatening Cancer: A Randomized Double-Blind Trial","volume":"30","author":"Griffiths RR","year":"2016","unstructured":"Griffiths RR, Johnson MW, Carducci MA et al (2016) Psilocybin Produces Substantial and Sustained Decreases in Depression and Anxiety in Patients With Life-Threatening Cancer: A Randomized Double-Blind Trial. J Psychopharmacol (Oxf) 30:1181\u20131197","journal-title":"J Psychopharmacol (Oxf)"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1001\/jama.2023.14530","article-title":"Single-Dose Psilocybin Treatment for Major Depressive Disorder: A Randomized Clinical Trial","volume":"330","author":"Raison CL","year":"2023","unstructured":"Raison CL, Sanacora G, Woolley J et al (2023) Single-Dose Psilocybin Treatment for Major Depressive Disorder: A Randomized Clinical Trial. JAMA 330:843","journal-title":"JAMA"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"103149","DOI":"10.1016\/j.eclinm.2025.103149","article-title":"Psilocybin-assisted therapy for relapse prevention in alcohol use disorder: a phase 2 randomized clinical trial","volume":"82","author":"Rieser NM","year":"2025","unstructured":"Rieser NM, Bitar R, Halm S et al (2025) Psilocybin-assisted therapy for relapse prevention in alcohol use disorder: a phase 2 randomized clinical trial. eClinicalMedicine 82:103149","journal-title":"eClinicalMedicine"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1177\/0269881116675512","article-title":"Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial","volume":"30","author":"Ross S","year":"2016","unstructured":"Ross S, Bossis A, Guss J et al (2016) Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. J Psychopharmacol (Oxf) 30:1165\u20131180","journal-title":"J Psychopharmacol (Oxf)"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.genhosppsych.2025.12.009","article-title":"Eligibility for Psychedelic Therapy: Clinical Trial Medical Exclusion Criteria and Their Implications for Hospital Practice","volume":"98","author":"Williams ML","year":"2026","unstructured":"Williams ML, Hitchcock K, Miller AH et al (2026) Eligibility for Psychedelic Therapy: Clinical Trial Medical Exclusion Criteria and Their Implications for Hospital Practice. Gen Hosp Psychiatry 98:116\u2013125","journal-title":"Gen Hosp Psychiatry"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1177\/02698811231179910","article-title":"Attenuation of psilocybin mushroom effects during and after SSRI\/SNRI antidepressant use","volume":"37","author":"Gukasyan N","year":"2023","unstructured":"Gukasyan N, Griffiths RR, Yaden DB et al (2023) Attenuation of psilocybin mushroom effects during and after SSRI\/SNRI antidepressant use. J Psychopharmacol (Oxf) 37:707\u2013716","journal-title":"J Psychopharmacol (Oxf)"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1056\/NEJMoa2106356","article-title":"Maintenance or Discontinuation of Antidepressants in Primary Care","volume":"385","author":"Lewis G","year":"2021","unstructured":"Lewis G, Marston L, Duffy L et al (2021) Maintenance or Discontinuation of Antidepressants in Primary Care. N Engl J Med 385:1257\u20131267","journal-title":"N Engl J Med"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1007\/s00213-021-05876-x","article-title":"Serotonin toxicity of serotonergic psychedelics","volume":"239","author":"Malcolm B","year":"2022","unstructured":"Malcolm B, Thomas K (2022) Serotonin toxicity of serotonergic psychedelics. Psychopharmacology 239:1881\u20131891","journal-title":"Psychopharmacology"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1177\/02698811211069100","article-title":"Adverse Effects of Psychedelics: From Anecdotes and Misinformation to Systematic Science","volume":"36","author":"Schlag AK","year":"2022","unstructured":"Schlag AK, Aday J, Salam I et al (2022) Adverse Effects of Psychedelics: From Anecdotes and Misinformation to Systematic Science. J Psychopharmacol (Oxf) 36:258\u2013272","journal-title":"J Psychopharmacol (Oxf)"},{"key":"ref31","unstructured":"Oregon Health Authority (2025) Client Information Form for Psilocybin Services, https:\/\/www.oregon.gov\/oha\/PH\/PREVENTIONWELLNESS\/Documents\/Client-Information-Form.pdf"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"105384","DOI":"10.1016\/j.drugpo.2026.105384","article-title":"Balancing Safety and Access in Oregon\u2019s Psilocybin Services","volume":"155","author":"Cheung K","year":"2026","unstructured":"Cheung K, Propes C, Yaden DB (2026) Balancing Safety and Access in Oregon\u2019s Psilocybin Services. Int J Drug Policy 155:105384","journal-title":"Int J Drug Policy"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1080\/02791072.2025.2454474","article-title":"Oregon\u2019s Emerging Psilocybin Services Workforce: A Survey of the First Legal Psilocybin Facilitators and Their Training Programs","volume":"58","author":"Luoma JB","year":"2026","unstructured":"Luoma JB, Hoffman K, Wilson-Poe AR et al (2026) Oregon\u2019s Emerging Psilocybin Services Workforce: A Survey of the First Legal Psilocybin Facilitators and Their Training Programs. J Psychoact Drugs 58:305\u2013315","journal-title":"J Psychoact Drugs"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1177\/02698811251362390","article-title":"Investigating the safety and tolerability of single-dose psilocybin for post-traumatic stress disorder: A nonrandomized open-label clinical trial","volume":"40","author":"McGowan NM","year":"2025","unstructured":"McGowan NM, Rucker JJ, Yehuda R et al (2025) Investigating the safety and tolerability of single-dose psilocybin for post-traumatic stress disorder: A nonrandomized open-label clinical trial. J Psychopharmacol Oxf Engl 40:139\u2013148","journal-title":"J Psychopharmacol Oxf Engl"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1038\/s41591-023-02565-4","article-title":"MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial","volume":"29","author":"Mitchell JM","year":"2023","unstructured":"Mitchell JM, Ot\u2019alora GM, van der Kolk B et al (2023) MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial. Nat Med 29:2473\u20132480","journal-title":"Nat Med"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.3389\/fpain.2025.1527783","article-title":"Preliminary safety and effectiveness of psilocybin-assisted therapy in adults with fibromyalgia: an open-label pilot clinical trial","volume":"6","author":"Aday JS","unstructured":"Aday JS, McAfee J, Conroy DA et al Preliminary safety and effectiveness of psilocybin-assisted therapy in adults with fibromyalgia: an open-label pilot clinical trial. Front Pain Res ; 6. Epub ahead of print 18 March 2025. 10.3389\/fpain.2025.1527783","journal-title":"Front Pain Res"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.4088\/JCP.v67n1110","article-title":"Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder","volume":"67","author":"Moreno FA","year":"2006","unstructured":"Moreno FA, Wiegand CB, Taitano EK et al (2006) Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder. J Clin Psychiatry 67:1735\u20131740","journal-title":"J Clin Psychiatry"},{"key":"ref38","unstructured":"Oregon Secretary of State Administrative Rules (2026) https:\/\/secure.sos.state.or.us\/oard\/viewSingleRule.action?ruleVrsnRsn=319992 (accessed 9 August"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/www.researchsquare.com\/article\/rs-10779254\/v2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.researchsquare.com\/article\/rs-10779254\/v2.html","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T18:42:42Z","timestamp":1787769762000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.researchsquare.com\/article\/rs-10779254\/v2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,26]]},"references-count":38,"URL":"https:\/\/doi.org\/10.21203\/rs.3.rs-10779254\/v2","relation":{"is-version-of":[{"id-type":"doi","id":"10.21203\/rs.3.rs-10779254\/v1","asserted-by":"subject"}]},"subject":[],"published":{"date-parts":[[2026,8,26]]},"subtype":"preprint"}}